Part 6: Advanced cardiovascular life support - Section 5: Pharmacology I: Agents for arrhythmias

Resuscitation

Volumn 46, Issue 1-3, 2000, Pages 135-153

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADRENALIN; AMIODARONE; ANTIARRHYTHMIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; BRETYLIUM; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHLORIDE; DILTIAZEM; DIPYRIDAMOLE; DISOPYRAMIDE; DOPAMINE; FIBRINOLYTIC AGENT; FLECAINIDE; IBUTILIDE; ISOPRENALINE; LIDOCAINE; MAGNESIUM; METHYLXANTHINE DERIVATIVE; PHENYTOIN; PROCAINAMIDE; PROPAFENONE; SOTALOL; THEOBROMINE; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL;

CENTRAL VEIN; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INDUCED DISEASE; EMERGENCY HEALTH SERVICE; HEART ARRHYTHMIA; HUMAN; PERIPHERAL VEIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESUSCITATION; REVIEW;

EID: 0034705948     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9572(00)00278-1     Document Type: Note

References (166)

1. Kuhn G.J., White B.C., Swetnam R.E., Mumey J.F., Rydesky M.F., Tintinalli J.E., Krome R.L., Hoehner P.J. Peripheral vs central circulation times during CPR: a pilot study. Ann Emerg Med. 10:1981;417-419.
2. Hedges J.R., Barsan W.B., Doan L.A., Joyce S.M., Lukes S.J., Dalsey W.C., Nishiyama H. Central versus peripheral intravenous routes in cardiopulmonary resuscitation. Am J Emerg Med. 2:1984;385-390.
3. Barsan W.G., Levy R.C., Weir H. Lidocaine levels during CPR: differences after peripheral venous, central venous, and intracardiac injections. Ann Emerg Med. 10:1981;73-78.
4. Emerman C.L., Pinchak A.C., Hancock D., Hagen J.F. Effect of injection site on circulation times during cardiac arrest [see comments]. Crit Care Med. 16:1988;1138-1141.
5. Emerman C.L., Bellon E.M., Lukens T.W. A prospective study of femoral versus subclavian vein catheterization during cardiac arrest. Ann Emerg Med. 19:1990;26-30.
6. Jasani M.S., Nadkarni V.M., Finkelstein M.S., Mandell G.A., Salzman S.K., Norman M.E. Effects of different techniques of endotracheal epinephrine administration in pediatric porcine hypoxic-hypercarbic cardiopulmonary arrest [see comments]. Crit Care Med. 22:1994;1174-1180.
7. Mazkereth R., Paret G., Ezra D., Aviner S., Peleg E., Rosenthal T., Barzilay Z. Epinephrine blood concentrations after peripheral bronchial versus endotracheal administration of epinephrine in dogs. Crit Care Med. 20:1992;1582-1587.
8. Johnston C. Endotracheal drug delivery. Pediatr Emerg Care. 8:1992;94-97.
9. Schnittger I., Rodriguez I.M., Winkle R.A. Esophageal electrocardiography: a new technology revives an old technique. Am J Cardiol. 57:1986;604-607.
10. Shaw M., Niemann J.T., Haskell R.J., Rothstein R.J., Laks M.M. Esophageal electrocardiography in acute cardiac care: efficacy and diagnostic value of a new technique. Am J Med. 82:1987;689-696.
11. Katz A., Guetta V., Ovsyshcher I.A. Transesophageal electrocardiography using a temporary pacing balloon-tipped electrode in acute cardiac care. Ann Emerg Med. 20:1991;961-963.
12. Lopez J.A., Lufschanowski R., Massumi A. Transesophageal electrocardiography and adenosine in the diagnosis of wide complex tachycardia. Tex Heart Inst J. 21:1994;130-133.
13. Stewart R.B., Bardy G.H., Greene H.L. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med. 104:1986;766-771.
14. Akhtar M., Shenasa M., Jazayeri M., Caceres J., Tchou P.J., Wide Q.R.S. complex tachycardia: reappraisal of a common clinical problem. Ann Intern Med. 109:1988;905-912.
15. Brugada P., Brugada J., Mont L., Smeets J., Andries E.W. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex [see comments]. Circulation. 83:1991;1649-1659.
16. Antunes E., Brugada J., Steurer G., Andries E., Brugada P. The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway [see comments]. Pacing Clin Electrophysiol. 17:1994;1515-1524.
17. Steurer G., Gursoy S., Frey B., Simonis F., Andries E., Kuck K., Brugada P. The differential diagnosis on the electrocardiogram between ventricular tachycardia and preexcited tachycardia. Clin Cardiol. 17:1994;306-308.
18. Wellens H.J., Bar F.W., Lie K.I. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med. 64:1978;27-33.
19. Kindwall K.E., Brown J., Josephson M.E. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol. 61:1988;1279-1283.
20. Halperin B.D., Kron J., Cutler J.E., Kudenchuk P.J., McAnulty J.H. Misdiagnosing ventricular tachycardia in patients with underlying conduction disease and similar sinus and tachycardia morphologies. West J Med. 152:1990;677-682.
21. Littmann L., McCall M.M. Ventricular tachycardia may masquerade as supraventricular tachycardia in patients with preexisting bundle-branch block. Ann Emerg Med. 26:1995;98-101.
22. Alberca T., Almendral J., Sanz P., Almazan A., Cantalapiedra J.L., Delcan J.L. Evaluation of the specificity of morphological electrocardiographic criteria for the differential diagnosis of wide QRS complex tachycardia in patients with intraventricular conduction defects. Circulation. 96:1997;3527-3533.
23. Herbert M.E., Votey S.R., Morgan M.T., Cameron P., Dziukas L. Failure to agree on the electrocardiographic diagnosis of ventricular tachycardia [see comments]. Ann Emerg Med. 27:1996;35-38.
24. Andrade F.R., Eslami M., Elias J., Kinoshita O., Nakazato Y., Marcus F.I., Frank R., Tonet J., Fontaine G. Diagnostic clues from the surface ECG to identify idiopathic (fascicular) ventricular tachycardia: correlation with electrophysiologic findings. J Cardiovasc Electrophysiol. 7:1996;2-8.
25. Lie K.I., Wellens H.J., van Capelle F.J., Durrer D. Lidocaine in the prevention of primary ventricular fibrillation: a double-blind, randomized study of 212 consecutive patients. N Engl J Med. 291:1974;1324-1326.
26. MacMahon S., Collins R., Peto R., Koster R.W., Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA. 260:1988;1910-1916.
27. Hine L.K., Laird N., Hewitt P., Chalmers T.C. Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med. 149:1989;2694-2698.
28. Sadowski Z.P., Alexander J.H., Skrabucha B., Dyduszynski A., Kuch J., Nartowicz E., Swiatecka G., Kong D.F., Granger C.B. Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction [see comments]. Am Heart J. 137:1999;792-798.
29. Alexander J.H., Granger C.B., Sadowski Z., Aylward P.E., White H.D., Thompson T.D., Califf R.M., Topol E.J. the GUSTO-I and GUSTO-IIb Investigators. Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials [see comments]. Am Heart J. 137:1999;799-805.
30. Armengol R.E., Graff J., Baerman J.M., Swiryn S. Lack of effectiveness of lidocaine for sustained, wide QRS complex tachycardia. Ann Emerg Med. 18:1989;254-257.
31. Nasir N. Jr, Taylor A., Doyle T.K., Pacifico A. Evaluation of intravenous lidocaine for the termination of sustained monomorphic ventricular tachycardia in patients with coronary artery disease with or without healed myocardial infarction. Am J Cardiol. 74:1994;1183-1186.
32. Gorgels A.P., van den Dool A., Hofs A., Mulleneers R., Smeets J.L., Vos M.A., Wellens H.J. Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia [see comments]. Am J Cardiol. 78:1996;43-46.
33. Ho D.S., Zecchin R.P., Richards D.A., Uther J.B., Ross D.L. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia [see comments]. Lancet. 344:1994;18-23.
34. Griffith M.J., Linker N.J., Ward D.E., Camm A.J. Adenosine in the diagnosis of broad complex tachycardia. Lancet. 1:1988;672-675.
35. Griffith M.J., Linker N.J., Garratt C.J., Ward D.E., Camm A.J. Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia. Lancet. 336:1990;670-673.
36. Sharma A.D., Klein G.J., Yee R. Intravenous adenosine triphosphate during wide QRS complex tachycardia: safety, therapeutic efficacy, and diagnostic utility. Am J Med. 88:1990;337-343.
37. Garratt C.J., Griffith M.J., O'Nunain S., Ward D.E., Camm A.J. Effects of intravenous adenosine on antegrade refractoriness of accessory atrioventricular connections. Circulation. 84:1991;1962-1968.
38. Brodsky M.A., Hwang C., Hunter D., Chen P.S., Smith D., Ariani M., Johnston W.D., Allen B.J., Chun J.G., Gold C.R. Life-threatening alterations in heart rate after the use of adenosine in atrial flutter. Am Heart J. 130:1995;564-571.
39. Callans D.J., Marchlinski F.E. Dissociation of termination and prevention of inducibility of sustained ventricular tachycardia with infusion of procainamide: evidence for distinct mechanisms. J Am Coll Cardiol. 19:1992;111-117.
40. Giardina E.G., Heissenbuttel R.H., Bigger J.T. Jr. Intermittent intravenous procaine amide to treat ventricular arrhythmias: correlation of plasma concentration with effect on arrhythmia, electrocardiogram, and blood pressure. Ann Intern Med. 78:1973;183-193.
41. Mattioli A.V., Lucchi G.R., Vivoli D., Mattioli G. Propafenone versus procainamide for conversion of atrial fibrillation to sinus rhythm. Clin Cardiol. 21:1998;763-766.
42. Kochiadakis G.E., Igoumenidis N.E., Solomou M.C., Parthenakis F.I., Christakis-Hampsas M.G., Chlouverakis G.I., Tsatsakis A.M., Vardas P.E. Conversion of atrial fibrillation to sinus rhythm using acute intravenous procainamide infusion. Cardiovasc Drugs Ther. 12:1998;75-81.
43. Heisel A., Jung J., Stopp M., Schieffer H. Facilitating influence of procainamide on conversion of atrial flutter by rapid atrial pacing. Eur Heart J. 18:1997;866-869.
44. Stambler B.S., Wood M.A., Ellenbogen K.A. Comparative efficacy of intravenous ibutilide versus procainamide for enhancing termination of atrial flutter by atrial overdrive pacing. Am J Cardiol. 77:1996;960-966.
45. Hjelms E. Procainamide conversion of acute atrial fibrillation after open-heart surgery compared with digoxin treatment. Scand J Thorac Cardiovasc Surg. 26:1992;193-196.
46. Fulham M.J., Cookson W.O., Sher M. Procainamide infusion and acute atrial fibrillation. Anaesth Intensive Care. 12:1984;121-124.
47. Fenster P.E., Comess K.A., Marsh R., Katzenberg C., Hager W.D. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 106:1983;501-504.
48. Mandel W.J., Laks M.M., Obayashi K., Hayakawa H., Daley W. The Wolff-Parkinson-White syndrome: pharmacologic effects of procaine amide. Am Heart J. 90:1975;744-754.
49. Leitch J.W., Klein G.J., Yee R., Feldman R.D., Brown J. Differential effect of intravenous procainamide on anterograde and retrograde accessory pathway refractoriness. J Am Coll Cardiol. 19:1992;118-124.
50. Boahene K.A., Klein G.J., Yee R., Sharma A.D., Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length [see comments]. J Am Coll Cardiol. 16:1990;1408-1414.
51. Wellens H.J., Braat S., Brugada P., Gorgels A.P., Bar F.W. Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway. Am J Cardiol. 50:1982;1087-1089.
52. Sellers T.D. Jr, Campbell R.W., Bashore T.M., Gallagher J.J. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation. 55:1977;15-22.
53. Gomes J.A., Kang P.S., Hariman R.J., El-Sherif N., Lyons J. Electrophysiologic effects and mechanisms of termination of supraventricular tachycardia by intravenous amiodarone. Am Heart J. 107:1984;214-221.
54. Noc M., Stajer D., Horvat M. Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm [see comments]. Am J Cardiol. 65:1990;679-680.
55. Galve E., Rius T., Ballester R., Artaza M.A., Arnau J.M., Garcia-Dorado D., Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study [see comments]. J Am Coll Cardiol. 27:1996;1079-1082.
56. Cochrane A.D., Siddins M., Rosenfeldt F.L., Salamonsen R., McConaghy L., Marasco S., Davis B.B. A comparison of amiodarone and digoxin for treatment of supraventricular arrhythmias after cardiac surgery. Eur J Cardiothorac Surg. 8:1994;194-198.
57. Vietti-Ramus G., Veglio F., Marchisio U., Burzio P., Latini R. Efficacy and safety of short intravenous amiodarone in supraventricular tachyarrhythmias. Int J Cardiol. 35:1992;77-85.
58. Bertini G., Conti A., Fradella G., Francardelli L., Giglioli C., Mangialavori G., Margheri M., Moschi G. Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med. 8:1990;15-20.
59. Mehta A.V., Sanchez G.R., Sacks E.J., Casta A., Dunn J.M., Donner R.M. Ectopic automatic atrial tachycardia in children: clinical characteristics, management and follow-up. J Am Coll Cardiol. 11:1988;379-385.
60. Holt P., Crick J.C., Davies D.W., Curry P. Intravenous amiodarone in the acute termination of supraventricular arrhythmias. Int J Cardiol. 8:1985;67-79.
61. Kochiadakis G.E., Igoumenidis N.E., Simantirakis E.N., Marketou M.E., Parthenakis F.I., Mezilis N.E., Vardas P.E. Intravenous propafenone versus intravenous amiodarone in the management of atrial fibrillation of recent onset: a placebo-controlled study. Pacing Clin Electrophysiol. 21:1998;2475-2479.
62. Clemo H.F., Wood M.A., Gilligan D.M., Ellenbogen K.A. Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol. 81:1998;594-598.
63. Cybulski J., Kulakowski P., Makowska E., Czepiel A., Sikora-Frac M., Ceremuzynski L. Intravenous amiodarone is safe and seems to be effective in termination of paroxysmal supraventricular tachyarrhythmias. Clin Cardiol. 19:1996;563-566.
64. Larbuisson R., Venneman I., Stiels B. The efficacy and safety of intravenous propafenone versus intravenous amiodarone in the conversion of atrial fibrillation or flutter after cardiac surgery. J Cardiothorac Vasc Anesth. 10:1996;229-234.
65. Kerin N.Z., Faitel K., Naini M. The efficacy of intravenous amiodarone for the conversion of chronic atrial fibrillation: amiodarone vs quinidine for conversion of atrial fibrillation [see comments]. Arch Intern Med. 156:1996;49-53.
66. Donovan K.D., Power B.M., Hockings B.E., Dobb G.J., Lee K.Y. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am J Cardiol. 75:1995;693-697.
67. Hou Z.Y., Chang M.S., Chen C.Y., Tu M.S., Lin S.L., Chiang H.T., Woosley R.L. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: a randomized, digoxin-controlled study [see comments]. Eur Heart J. 16:1995;521-528.
68. Di Biasi P, Scrofani R, Paje A, Cappiello E., Mangini A., Santoli C. Intravenous amiodarone vs propafenone for atrial fibrillation and flutter after cardiac operation [see comments]. Eur J Cardiothorac Surg. 9:1995;587-591.
69. Chapman M.J., Moran J.L., O'Fathartaigh M.S., Peisach A.R., Cunningham D.N. Management of atrial tachyarrhythmias in the critically ill: a comparison of intravenous procainamide and amiodarone. Intensive Care Med. 19:1993;48-52.
70. Horner S.M. A comparison of cardioversion of atrial fibrillation using oral amiodarone, intravenous amiodarone and DC cardioversion [published erratum appears in Acta Cardiol. 1992;47:following table of contents]. Acta Cardiol. 47:1992;473-480.
71. Cowan J.C., Gardiner P., Reid D.S., Newell D.J., Campbell R.W. A comparison of amiodarone and digoxin in the treatment of atrial fibrillation complicating suspected acute myocardial infarction. J Cardiovasc Pharmacol. 8:1986;252-256.
72. Strasberg B., Arditti A., Sclarovsky S., Lewin R.F., Buimovici B., Agmon J. Efficacy of intravenous amiodarone in the management of paroxysmal or new atrial fibrillation with fast ventricular response. Int J Cardiol. 7:1985;47-58.
73. Faniel R., Schoenfeld P. Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. Eur Heart J. 4:1983;180-185.
74. Soult J.A., Munoz M., Lopez J.D., Romero A., Santos J., Tovaruela A. Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children. Pediatr Cardiol. 16:1995;16-19.
75. Sagrista-Sauleda J., Permanyer-Miralda G., Soler-Soler J. Electrical cardioversion after amiodarone administration. Am Heart J. 123:1992;1536-1542.
76. Butler J., Harriss D.R., Sinclair M., Westaby S. Amiodarone prophylaxis for tachycardias after coronary artery surgery: a randomised, double blind, placebo controlled trial. Br Heart J. 70:1993;56-60.
77. Holt A.W. Hemodynamic responses to amiodarone in critically ill patients receiving catecholamine infusions. Crit Care Med. 17:1989;1270-1276.
78. Leak D. Intravenous amiodarone in the treatment of refractory life-threatening cardiac arrhythmias in the critically ill patient. Am Heart J. 111:1986;456-462.
79. Kuga K., Yamaguchi I., Sugishita Y. Effect of intravenous amiodarone on electrophysiologic variables and on the modes of termination of atrioventricular reciprocating tachycardia in Wolff-Parkinson-White syndrome. Jpn Circ J. 63:1999;189-195.
80. Kouvaras G., Cokkinos D.V., Halal G., Chronopoulos G., Ioannou N. The effective treatment of multifocal atrial tachycardia with amiodarone. Jpn Heart J. 30:1989;301-312.
81. Figa F.H., Gow R.M., Hamilton R.M., Freedom R.M. Clinical efficacy and safety of intravenous amiodarone in infants and children. Am J Cardiol. 74:1994;573-577.
82. Mooss A.N., Mohiuddin S.M., Hee T.T., Esterbrooks D.J., Hilleman D.E., Rovang K.S., Sketch M.H. Sr. Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. Am J Cardiol. 65:1990;609-614.
83. Schutzenberger W., Leisch F., Kerschner K., Harringer W., Herbinger W. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Br Heart J. 62:1989;367-371.
84. Helmy I., Herre J.M., Gee G., Sharkey H., Malone P., Sauve M.J., Griffin J.C., Scheinman M.M. Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. J Am Coll Cardiol. 12:1988;1015-1022.
85. Saksena S., Rothbart S.T., Shah Y., Cappello G. Clinical efficacy and electropharmacology of continuous intravenous amiodarone infusion and chronic oral amiodarone in refractory ventricular tachycardia. Am J Cardiol. 54:1984;347-352.
86. Remme W.J., Van Hoogenhuyze D.C., Krauss X.H., Hofman A., Kruyssen D.A., Storm C.J. Acute hemodynamic and antiischemic effects of intravenous amiodarone. Am J Cardiol. 55:1985;639-644.
87. Kowey P.R., Levine J.H., Herre J.M., Pacifico A., Lindsay B.D., Plumb V.J., Janosik D.L., Kopelman H.A., Scheinman M.M. the Intravenous Amio-darone Multicenter Investigators Group. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation [see comments]. Circulation. 92:1995;3255-3263.
88. Levine J.H., Massumi A., Scheinman M.M., Winkle R.A., Platia E.V., Chilson D.A., Gomes A., Woosley R.L. Intravenous Amiodarone Multicenter Trial Group. Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. J Am Coll Cardiol. 27:1996;67-75.
89. Scheinman M.M., Levine J.H., Cannom D.S., Friehling T., Kopelman H.A., Chilson D.A., Platia E.V., Wilber D.J., Kowey P.R. the Intravenous Amio-darone Multicenter Investigators Group. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias [see comments]. Circulation. 92:1995;3264-3272.
90. Remme W.J., Kruyssen H.A., Look M.P., van Hoogenhuyze D.C., Krauss X.H. Hemodynamic effects and tolerability of intravenous amiodarone in patients with impaired left ventricular function. Am Heart J. 122:1991;96-103.
91. Kudenchuk P.J., Cobb L.A., Copass M.K., Cummins R.O., Doherty A.M., Fahrenbruch C.E., Hallstrom A.P., Murray W.A., Olsufka M., Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 341:1999;871-878.
92. Jawad-Kanber G., Sherrod T.R. Effect of loading dose of procainamide on left ventricular performance in man. Chest. 66:1974;269-272.
93. Harrison D.C., Sprouse J.H., Morrow A.G. The antiarrhythmic properties of lidocaine and procaine amide. Circulation. 28:1963;486-491.
94. Brady W.J., DeBehnke D.J., Laundrie D. Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes. Acad Emerg Med. 6:1999;609-617.
95. Totterman K.J., Turto H., Pellinen T. Overdrive pacing as treatment of sotalol-induced ventricular tachyarrhythmias (torsade de pointes). Acta Med Scand Suppl. 668:1982;28-33.
96. Inoue H., Matsuo H., Mashima S., Murao S. Effects of atrial pacing, isoprenaline and lignocaine on experimental polymorphous ventricular tachycardia. Cardiovasc Res. 18:1984;538-547.
97. Assimes T.L., Malcolm I. Torsade de pointes with sotalol overdose treated successfully with lidocaine. Can J Cardiol. 14:1998;753-756.
98. Hondeghem L.M. Selective depression of the ischemic and hypoxic myocardium by lidocaine. Proc West Pharmacol Soc. 18:1975;27-30.
99. Borer J.S., Harrison L.A., Kent K.M., Levy R., Goldstein R.E., Epstein S.E. Beneficial effect of lidocaine on ventricular electrical stability and spontaneous ventricular fibrillation during experimental myocardial infarction. Am J Cardiol. 37:1976;860-863.
100. Spear J.F., Moore E.N., Gerstenblith G. Effect of lidocaine on the ventricular fibrillation threshold in the dog during acute ischemia and premature ventricular contractions. Circulation. 46:1972;65-73.
101. Carden N.J., Steinhaus J.E. Lidocaine in cardiac resuscitation from ventricular fibrillation. Circ Res. 1956;4.
102. Lazzara R., el-Sherif N., Scherlag B.J. Electrophysiological properties of canine Purkinje cells in one-day-old myocardial infarction. Circ Res. 33:1973;722-734.
103. Lazzara R., Hope R.R., El-Sherif N., Scherlag B.J. Effects of lidocaine on hypoxic and ischemic cardiac cells. Am J Cardiol. 41:1978;872-879.
104. Hanyok J.J., Chow M.S., Kluger J., Fieldman A. Antifibrillatory effects of high dose bretylium and a lidocaine-bretylium combination during cardiopulmonary resuscitation. Crit Care Med. 16:1988;691-694.
105. Herlitz J., Ekstrom L., Wennerblom B., Axelsson A., Bang A., Lindkvist J., Persson N.G., Holmberg S. Lidocaine in out-of-hospital ventricular fibrillation: does it improve survival? Resuscitation. 33:1997;199-205.
106. Harrison E.E. Lidocaine in prehospital countershock refractory ventricular fibrillation. Ann Emerg Med. 10:1981;420-423.
107. Haynes R.E., Chinn T.L., Copass M.K., Cobb L.A. Comparison of bretylium tosylate and lidocaine in management of out of hospital ventricular fibrillation: a randomized clinical trial. Am J Cardiol. 48:1981;353-356.
108. Olson D.W., Thompson B.M., Darin J.C., Milbrath M.H. A randomized comparison study of bretylium tosylate and lidocaine in resuscitation of patients from out-of-hospital ventricular fibrillation in a paramedic system. Ann Emerg Med. 13:1984;807-810.
109. Kentsch M., Berkel H., Bleifeld W. Intravenose Amiodaron-Applikation bei therapierefraktarem Kammerflimmern. Intensivmedizin. 25:1988;70-74.
110. Weaver W.D., Fahrenbruch C.E., Johnson D.D., Hallstrom A.P., Cobb L.A., Copass M.K. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 82:1990;2027-2034.
111. van Walraven C., Stiell I.G., Wells G.A., Hebert P.C., Vandemheen K., the O.T.A.C. Study Group. Do advanced cardiac life support drugs increase resuscitation rates from in-hospital cardiac arrest? Ann Emerg Med. 32:1998;544-553.
112. Redding J.S., Pearson J.W. Resuscitation from ventricular fibrillation: drug therapy. JAMA. 203:1968;255-260.
113. Chow M.S., Kluger J., Lawrence R., Fieldman A. The effect of lidocaine and bretylium on the defibrillation threshold during cardiac arrest and cardiopulmonary resuscitation. Proc Soc Exp Biol Med. 182:1986;63-67.
114. Babbs C.F., Yim G.K., Whistler S.J., Tacker W.A., Geddes L.A. Elevation of ventricular defibrillation threshold in dogs by antiarrhythmic drugs. Am Heart J. 98:1979;345-350.
115. Echt D.S., Black J.N., Barbey J.T., Coxe D.R., Cato E. Evaluation of antiarrhythmic drugs on defibrillation energy requirements in dogs: sodium channel block and action potential prolongation. Circulation. 79:1989;1106-1117.
116. Dorian P., Fain E.S., Davy J.M., Winkle R.A. Lidocaine causes a reversible, concentration-dependent increase in defibrillation energy requirements. J Am Coll Cardiol. 8:1986;327-332.
117. Kerber R.E., Pandian N.G., Jensen S.R., Constantin L., Kieso R.A., Melton J., Hunt M. Effect of lidocaine and bretylium on energy requirements for transthoracic defibrillation: experimental studies. J Am Coll Cardiol. 7:1986;397-405.
118. Vachiery J.L., Reuse C., Blecic S., Contempre B., Vincent J.L. Bretylium tosylate versus lidocaine in experimental cardiac arrest [see comments]. Am J Emerg Med. 8:1990;492-495.
119. Anastasiou-Nana M.I., Nanas J.N., Nanas S.N., Rapti A., Poyadjis A., Stathaki S., Moulopoulos S.D. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. J Am Coll Cardiol. 23:1994;253-258.
120. Stiell I.G., Wells G.A., Hebert P.C., Laupacis A., Weitzman B.N. Association of drug therapy with survival in cardiac arrest: limited role of advanced cardiac life support drugs. Acad Emerg Med. 2:1995;264-273.
121. Tzivoni D., Keren A., Cohen A.M., Loebel H., Zahavi I., Chenzbraun A., Stern S. Magnesium therapy for torsades de pointes. Am J Cardiol. 53:1984;528-530.
122. Tzivoni D., Banai S., Schuger C., Benhorin J., Keren A., Gottlieb S., Stern S. Treatment of torsade de pointes with magnesium sulfate. Circulation. 77:1988;392-397.
123. Miller B., Craddock L., Hoffenberg S., Heinz S., Lefkowitz D., Callender M.L., Battaglia C., Maines C., Masick D. Pilot study of intravenous magnesium sulfate in refractory cardiac arrest: safety data and recommendations for future studies. Resuscitation. 30:1995;3-14.
124. Thel M.C., Armstrong A.L., McNulty S.E., Califf R.M., O'Connor C.M. Duke Internal Medicine Housestaff. Randomised trial of magnesium in in-hospital cardiac arrest [see comments]. Lancet. 350:1997;1272-1276.
125. Kudenchuk P.D., Cobb L., Fahrenbruch C., Doherty A., Murray W., et al. The ARREST Trial. Randomized controlled trial of Amiodarone vs Placebo in the early treatment of refractory VF arrest in the out-of-hospital setting. Circulation. 1997;96.
126. Moran J.L., Gallagher J., Peake S.L., Cunningham D.N., Salagaras M., Leppard P. Parenteral magnesium sulfate versus amiodarone in the therapy of atrial tachyarrhythmias: a prospective, randomized study. Crit Care Med. 23:1995;1816-1824.
127. O'Nunain S., Garratt C.J., Linker N.J., Gill J., Ward D.E., Camm A.J. A comparison of intravenous propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol. 14:1991;2028-2034.
128. Jordaens L., Gorgels A., Stroobandt R., Temmerman J. the Sotalol Versus Placebo Multicenter Study Group. Efficacy and safety of intravenous sotalol for termination of paroxysmal supraventricular tachycardia. Am J Cardiol. 68:1991;35-40.
129. Sung R.J., Tan H.L., Karagounis L., Hanyok J.J., Falk R., Platia E., Das G., Hardy S.A. Sotalol Multicenter Study Group. Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Am Heart J. 129:1995;739-748.
130. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., Arensberg D., Baker A., Friedman L., Greene H.L., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial [see comments]. N Engl J Med. 324:1991;781-788.
131. Hellestrand K.J. Intravenous flecainide acetate for supraventricular tachycardias. Am J Cardiol. 62:1988;16D-22D.
132. Kuck K.H., Kunze K.P., Schluter M., Duckeck W. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. Am J Cardiol. 62:1988;37L-44L.
133. Reimer A., Paul T., Kallfelz H.C. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol. 68:1991;741-744.
134. Bauersfeld U., Gow R.M., Hamilton R.M., Izukawa T. Treatment of atrial ectopic tachycardia in infants < 6 months old. Am Heart J. 129:1995;1145-1148.
135. Tommaso C., McDonough T., Parker M., Talano J.V. Atrial fibrillation and flutter: immediate control and conversion with intravenously administered verapamil. Arch Intern Med. 143:1983;877-881.
136. Phillips B.G., Gandhi A.J., Sanoski C.A., Just V.L., Bauman J.L. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter. Pharmacotherapy. 17:1997;1238-1245.
137. Hwang M.H., Danoviz J., Pacold I., Rad N., Loeb H.S., Gunnar R.M. Double-blind crossover randomized trial of intravenously administered verapamil: its use for atrial fibrillation and flutter following open heart surgery. Arch Intern Med. 144:1984;491-494.
138. Gray R.J., Conklin C.M., Sethna D.H., Mandel W.J., Matloff J.M. Role of intravenous verapamil in supraventricular tachyarrhythmias after open-heart surgery. Am Heart J. 104:1982;799-802.
139. Gonzalez R., Scheinman M.M. Treatment of supraventricular arrhythmias with intravenous and oral verapamil. Chest. 80:1981;465-470.
140. Aronow W.S., Landa D., Plasencia G., Wong R., Karlsberg R.P., Ferlinz J. Verapamil in atrial fibrillation and atrial flutter. Clin Pharmacol Ther. 26:1979;578-583.
141. Haynes B.E., Niemann J.T., Haynes K.S. Supraventricular tachyarrhythmias and rate-related hypotension: cardiovascular effects and efficacy of intravenous verapamil [published erratum appears in Ann Emerg Med. 1991;20:671]. Ann Emerg Med. 19:1990;861-864.
142. Barnett J.C., Touchon R.C. Short-term control of supraventricular tachycardia with verapamil infusion and calcium pretreatment. Chest. 97:1990;1106-1109.
143. Heng M.K., Singh B.N., Roche A.H., Norris R.M., Mercer C.J. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J. 90:1975;487-498.
144. Schwartz M., Michelson E.L., Sawin H.S., MacVaugh H. III. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest. 93:1988;705-711.
145. Shettigar U.R., Toole J.G., Appunn D.O. Combined use of esmolol and digoxin in the acute treatment of atrial fibrillation or flutter. Am Heart J. 126:1993;368-374.
146. Gray R.J., Bateman T.M., Czer L.S., Conklin C.M., Matloff J.M. Esmolol: a new ultrashort-acting beta-adrenergic blocking agent for rapid control of heart rate in postoperative supraventricular tachyarrhythmias. J Am Coll Cardiol. 5:1985;1451-1456.
147. Byrd R.C., Sung R.J., Marks J., Parmley W.W. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll Cardiol. 3:1984;394-399.
148. Amsterdam E.A., Kulcyski J., Ridgeway M.G. Efficacy of cardioselective beta-adrenergic blockade with intravenously administered metoprolol in the treatment of supraventricular tachyarrhythmias. J Clin Pharmacol. 31:1991;714-718.
149. Rehnqvist N. Clinical experience with intravenous metoprolol in supraventricular tachyarrhythmias: a multicentre study. Ann Clin Res. ;13(suppl. 30:1981;68-72.
150. Platia E.V., Michelson E.L., Porterfield J.K., Das G. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 63:1989;925-929.
151. Tisdale J.E., Padhi I.D., Goldberg A.D., Silverman N.A., Webb C.R., Higgins R.S., Paone G., Frank D.M., Borzak S. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. Am Heart J. 135:1998;739-747.
152. Schreck D.M., Rivera A.R., Tricarico V.J. Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin [see comments]. Ann Emerg Med. 29:1997;135-140.
153. Boudonas G., Lefkos N., Efthymiadis A.P., Styliadis I.G., Tsapas G. Intravenous administration of diltiazem in the treatment of supraventricular tachyarrhythmias. Acta Cardiol. 50:1995;125-134.
154. Goldenberg I.F., Lewis W.R., Dias V.C., Heywood J.T., Pedersen W.R. Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure [see comments]. Am J Cardiol. 74:1994;884-889.
155. Salerno D.M., Dias V.C., Kleiger R.E., Tschida V.H., Sung R.J., Sami M., Giorgi L.V. the Diltiazem-Atrial Fibrillation/Flutter Study Group. Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. Am J Cardiol. 63:1989;1046-1051.
156. Millaire A., Leroy O., de Groote P., Santre C., Ducloux G. Usefulness of diltiazem in the acute management of supraventricular tachyarrhythmias in the elderly. Cardiovasc Drugs Ther. 10:1996;11-16.
157. Ellenbogen K.A., Dias V.C., Cardello F.P., Strauss W.E., Simonton C.A., Pollak S.J., Wood M.A., Stambler B.S. Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am J Cardiol. 75:1995;45-49.
158. Jordaens L., Trouerbach J., Calle P., Tavernier R., Derycke E., Vertongen P., Bergez B., Vandekerckhove Y. Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo [see comments]. Eur Heart J. 18:1997;643-648.
159. Heywood J.T., Graham B., Marais G.E., Jutzy K.R. Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure. Am J Cardiol. 67:1991;1150-1152.
160. Cotter G., Blatt A., Kaluski E., Metzkor-Cotter E., Koren M., Litinski I., Simantov R., Moshkovitz Y., Zaidenstein R., Peleg E., Vered Z., Golik A. Conversion of recent onset paroxysmal atrial fibrillation to normal sinus rhythm: the effect of no treatment and high-dose amiodarone: a randomized, placebo-controlled study [see comments]. Eur Heart J. 20:1999;1833-1842.
161. Touboul P., Atallah G., Kirkorian G., Lavaud P., Mathieu M.P., Dellinger A. Effects of intravenous sotalol in patients with atrioventricular accessory pathways. Am Heart J. 114:1987;545-550.
162. Camm A.J., Garratt C.J. Adenosine and supraventricular tachycardia [see comments]. N Engl J Med. 325:1991;1621-1629.
163. Bersten A.D., Holt A.W. Vasoactive drugs and the importance of renal perfusion pressure. New Horiz. 3:1995;650-661.
164. Marik P.E. Low-dose dopamine in critically ill oliguric patients: the influence of the renin-angiotensin system. Heart Lung. 22:1993;171-175.
165. Chertow G.M., Sayegh M.H., Allgren R.L., Lazarus J.M. Auriculin Anaritide Acute Renal Failure Study Group. Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? [see comments]. Am J Med. 101:1996;49-53.
166. Thadani R., Pascual M., Bonventre J. Acute renal failure. N Engl J Med. 334:1996;1448-1460.